Compare Amphastar Pharmaceuticals Inc (AMPH) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs SAP SE — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while SAP SE trades at $209.19 (market cap $239.15B). The key difference: SAP SE is far larger — about 276.8× Amphastar Pharmaceuticals Inc's market cap, and SAP SE pays a 1.4% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SAP | |
|---|---|---|
Market Cap | $863.95M | $239.15B |
Sector | Health | Technology |
52-Week High | $30.81 | $287.24 |
52-Week Low | $16.87 | $146.38 |
Enterprise Value | $1.26B | $237.86B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
SAP trades at $206.16, up 3.36% today, with a bullish technical outlook supported by moving averages and strong support at $204. The company reported Q2 2026 revenue growth driven by cloud demand but missed EPS estimates, with net income margin at 20.41% and a P/E of 26.71. Recent news highlights AI and cloud strategy advancements, though profit guidance was trimmed.
Outlook is cautiously optimistic with a consensus price target of $209.67, offering modest upside. Risks include execution challenges in AI integration and competitive pressures. Analyst sentiment is mixed, with 53% buy ratings, but high RSI levels suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
